StageZero Life Sciences Ltd.
SZLS.TO
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 09/30/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 499.70K | 390.10K | 521.90K | 745.50K | 745.50K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 499.70K | 390.10K | 521.90K | 745.50K | 745.50K |
| Cost of Revenue | 608.90K | 382.30K | 221.40K | 577.10K | 686.40K |
| Gross Profit | -109.20K | 7.80K | 300.50K | 168.40K | 59.10K |
| SG&A Expenses | 242.90K | 703.10K | 596.10K | 909.40K | 800.10K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 851.80K | 1.09M | 817.50K | 1.51M | 1.51M |
| Operating Income | -352.10K | -695.30K | -295.60K | -760.70K | -760.70K |
| Income Before Tax | -399.30K | -649.50K | -386.30K | -821.90K | -821.90K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -399.30K | -649.50K | -386.30K | -821.90K | -821.90K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -399.30K | -649.50K | -386.30K | -821.90K | -821.90K |
| EBIT | -352.10K | -695.30K | -295.60K | -760.70K | -760.70K |
| EBITDA | -337.00K | -651.50K | -277.30K | -722.60K | -722.60K |
| EPS Basic | 0.00 | -0.01 | 0.00 | -0.01 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| EPS Diluted | 0.00 | -0.01 | 0.00 | -0.01 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| Average Basic Shares Outstanding | 123.53M | 123.53M | 123.55M | 113.49M | 101.18M |
| Average Diluted Shares Outstanding | 123.53M | 123.53M | 123.55M | 113.49M | 101.18M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
